Market Herald logo


Be the first with the news that moves the market
  • Replicel Life Sciences (TSXV:RP) is experiencing production problems after a factory in China was shut down due to COVID-19
  • The Chinese factory produces a key component in the company’s new dermal injector range
  • RepliCel President and CEO, R. Lee Buckler has said the factory is expected to reopen this month but the company is still seeking a new manufacturer
  • The company is still hoping to launch the product this year
  • Replicel Life Sciences (RP) was down 29.17 per cent, with shares trading at C$0.17 and a market cap of $4.85 million

Replicel Life Sciences (TSXV:RP) is the latest company to experience production problems as a result of COVID-19 factory shutdowns in China.

The company announced last month that all parts for its new dermal injector had been ordered and they expected to launch the product in late 2020.

Replicel is currently developing therapies for skin repair and hair restoration. The dermal injectors are used in the therapies’ application.

However, a single component has been delayed since the Chinese manufacturer temporarily shutdown due to the the spread of COVID-19 in the region.

RepliCel President and CEO, R. Lee Buckler, hopes to resolve the issue expediently.

“While we have been informed that the plant is expected to be operational again in early March, we have already experienced several weeks’ delay in our production timeline.

“We are actively pursuing alternative suppliers and manufacturers in the event this does not resolve quickly, and are confident we will find a solution which supports our goal of market approval and product launch this year,” he said

Although Buckler stated that production should resume in early March, the company has not announced any firm date. With the factory still shut, and no new producer in site, the likelihood of a 2020 launch remains uncertain.

Upon launching, Replicel plans to seek regulatory approval for the dermal injectors in Europe, Hong Kong the United States and Japan. The company was quick to point out that all other components are still in production and on schedule.

Replicel Life Sciences (RP) was down 29.17 per cent, with shares trading for C$0.17 at 2.05pm EST.

More From The Market Herald

" WELL Health NCIB suggests undervaluation

WELL Health has entered into an automatic share purchase plan to facilitate share repurchases.

" Best biotech stocks to buy in 2023

Innovation continues to drive the broader healthcare market, and the best biotech stocks are at the forefront of new developments and therapies to

" Lifeist to acquire the fast-growing ‘Zest’ brand

Lifeist Wellness (TSXV:LFST) has signed a share purchase agreement to acquire the Zest brand.

" Advancing environmental work at the Frances Creek barium project

Voyageur Pharmaceuticals (TSXV:VM) has finished environmental and geotechnical field work at its Frances Creek project site.